
Nano-X Imaging (NNOX) Stock Forecast & Price Target
Nano-X Imaging (NNOX) Analyst Ratings
Bulls say
Nano X Imaging is showing improving top-line traction with growing revenue and a $35 million revenue target for 2026, supported by teleradiology growth, Nanox Health IT contribution, and expanding U.S. distribution of the Nanox.ARC. While the fourth-quarter experienced a non-cash impairment, the new distribution agreement with Imperial Imaging Technology is a significant step-up in channel scale, leveraging a national footprint and established procurement relationships to drive adoption in underserved settings. Nanox's strategy of closer-to-patient imaging is reinforced through this partnership, further supporting its commercialization thesis and potential for future growth.
Bears say
Nano X Imaging is facing challenges in converting its distribution agreements into meaningful revenue and requires additional financing for execution, making it heavily reliant on successful operation. The company's strategy of leveraging regional distributors for adoption and sales cycle reduction has shown positive signs but focused efforts on execution, especially with execution of Imperial Imaging. Furthermore, the removal of the adjunctive use limitation in the U.S. is critical for growth, as well as demonstrating broad utilization of its technology and securing additional financing.
This aggregate rating is based on analysts' research of Nano-X Imaging and is not a guaranteed prediction by Public.com or investment advice.
Nano-X Imaging (NNOX) Analyst Forecast & Price Prediction
Start investing in Nano-X Imaging (NNOX)
Order type
Buy in
Order amount
Est. shares
0 shares